Cancer
The global biopharmaceutical market is witnessing significant growth, driven by the increasing prevalence of chronic illnesses and rare diseases, along with the rising demand for biologics and precision therapies. The market value is estimated to reach $921.5 billion by 2034, growing at a compound annual growth rate (CAGR) of
Cancer
Researchers from Karpagam Academy of Higher Education in Coimbatore, India, have made significant strides in the development of personalized cancer therapies, shifting the focus from conventional methods like chemotherapy, radiation, and surgery. The study, published in Bioengineering, highlights the potential of drug-free cancer treatments, including high-intensity focused energy beams, nanosecond
Cancer
Researchers at Hangzhou Medical College have made significant progress in cancer therapy by developing a novel nanomedicine platform that combines bio-barrier-adaptable biomimetic properties with ultrasound-mediated intratumoral penetration. This innovative approach has achieved remarkable tumor growth inhibition in vivo, with a 96.5% efficacy rate while maintaining favorable biocompatibility. Key Takeaways:
Cancer
Researchers at Hanyang University have made a significant discovery in cancer therapy, developing fucoidan-chitosan nanocarriers that demonstrate high efficacy in reducing cancer cell viability while minimizing side effects. This innovative approach combines chemodynamic therapy, starvation therapy, and photothermal therapy to activate drug release and generate reactive oxygen species within the
Antineoplastic agents
Thousands of men in the UK with advanced prostate cancer are set to benefit from a groundbreaking at-home treatment, Relugolix, which has been approved by the National Institute for Health and Care Excellence (NICE) for use on the NHS. The pill, known by its brand name Orgovyx, is a major
Cancer
Recent research on oncology has highlighted the potential of cabozantinib, a novel multiple tyrosine-kinase targeted agent, in anti-angiogenic therapy for the treatment of various solid tumors. The study, conducted by researchers at the College of Pharmacy, revealed that cabozantinib has shown efficacy in inhibiting angiogenesis and cancer growth in preclinical
Cancer
Researchers at the University of Tsukuba in Japan have published a study evaluating the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric cancer. The study, which involved 685 patients, found that SOX was noninferior to CS
Cancer treatment
A recent phase 1b study published in the journal Clinical Cancer Research has shed new light on the treatment of advanced non-small cell lung cancer (NSCLC). Researchers from the University of Texas M.D. Anderson Cancer Center investigated the safety and efficacy of motesanib, an oral angiogenesis inhibitor, in combination
Drugs
Scientists at Kanazawa University's Cancer Research Institute have discovered a novel mechanism of resistance to irreversible epidermal growth factor receptor (EGFR) inhibitors in lung cancer patients. The study, published in Clinical Cancer Research, found that hepatocyte growth factor (HGF) reduces susceptibility to the irreversible EGFR tyrosine kinase inhibitor
Drugs
Recent research published in the British Journal of Pharmacology reveals that checkpoint kinase 2 (CHK2) modulates the response of colorectal cancer cells to oxaliplatin treatment. The study, led by I.M. Pires and colleagues from the University of Manchester, investigated the role of CHK2 in oxaliplatin-induced toxicity in colorectal cancer
Cancer treatment
Scientists from Korea have developed a novel approach to cancer gene therapy, utilizing a group I intron of Tetrahymena thermophila to target telomerase reverse transcriptase (TERT) activity in cancer cells. The TERT enzyme is highly upregulated in 85-90% of human cancers, making it a promising target for anticancer therapy. The
Cancer research
A new study has shed light on the effective localization of the sentinel lymph node (SLN) in tongue carcinoma using a combination of indirect computed tomography lymphography (CT-LG) with methylene blue dye injection. The research, conducted by H. Wu and colleagues at Fudan University in Shanghai, People's Republic
